233 related articles for article (PubMed ID: 32772926)
21. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.
Gockley A; Melamed A; Bregar AJ; Clemmer JT; Birrer M; Schorge JO; Del Carmen MG; Rauh-Hain JA
Obstet Gynecol; 2017 Mar; 129(3):439-447. PubMed ID: 28178043
[TBL] [Abstract][Full Text] [Related]
23. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
[TBL] [Abstract][Full Text] [Related]
24. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
Chan JK; Tian C; Fleming GF; Monk BJ; Herzog TJ; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):301-6. PubMed ID: 19945740
[TBL] [Abstract][Full Text] [Related]
25. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
[TBL] [Abstract][Full Text] [Related]
26. A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC).
Chen L; Liu X; Li M; Wang S; Zhou H; Liu L; Cheng X
Cancer Med; 2020 Feb; 9(3):988-998. PubMed ID: 31846222
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base.
Nasioudis D; Latif NA; Simpkins F; Cory L; Giuntoli RL; Haggerty AF; Morgan MA; Ko EM
Gynecol Oncol; 2020 Feb; 156(2):315-319. PubMed ID: 31839340
[TBL] [Abstract][Full Text] [Related]
28. Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma.
Zwart J; Geisler JP; Geisler HE
Eur J Gynaecol Oncol; 1998; 19(3):225-8. PubMed ID: 9641218
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience.
Bamias A; Karadimou A; Soupos N; Sotiropoulou M; Zagouri F; Haidopoulos D; Thomakos N; Rodolakis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2011 Oct; 123(1):37-42. PubMed ID: 21764430
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
Skírnisdóttir I; Lindborg K; Sorbe B
Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
[TBL] [Abstract][Full Text] [Related]
31. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer.
Matsuo K; Machida H; Frimer M; Marcus JZ; Pejovic T; Roman LD; Wright JD
Gynecol Oncol; 2017 Dec; 147(3):558-564. PubMed ID: 28986093
[TBL] [Abstract][Full Text] [Related]
33. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
Chishti U; Aziz AB
J Pak Med Assoc; 2015 Mar; 65(3):306-9. PubMed ID: 25933567
[TBL] [Abstract][Full Text] [Related]
34. Intraoperative Capsule Rupture, Postoperative Chemotherapy, and Survival of Women With Stage I Epithelial Ovarian Cancer.
Matsuo K; Machida H; Yamagami W; Ebina Y; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Enomoto T; Mikami M
Obstet Gynecol; 2019 Nov; 134(5):1017-1026. PubMed ID: 31599824
[TBL] [Abstract][Full Text] [Related]
35. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
36. [Rectosigmoidectomy following neoadjuvant chemotherapy for advanced ovarian cancer].
Kato T; Shimizu Y; Umezawa S; Hasumi K
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Dec; 46(12):1337-42. PubMed ID: 7852772
[TBL] [Abstract][Full Text] [Related]
37. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
[TBL] [Abstract][Full Text] [Related]
38. The Safety of Ovarian Preservation in Stage I Endometrial Endometrioid Adenocarcinoma Based on Propensity Score Matching.
Hou T; Sun Y; Li J; Liu C; Wang Z; Li Y; Lu Y
Comb Chem High Throughput Screen; 2017; 20(7):647-655. PubMed ID: 28413975
[TBL] [Abstract][Full Text] [Related]
39. Comparison of early-stage primary serous fallopian tube carcinomas and equivalent stage serous epithelial ovarian carcinomas.
Horng HC; Lai CR; Chang WH; Wen KC; Chen YJ; Juang CM; Yen MS; Wang PH
Taiwan J Obstet Gynecol; 2014 Dec; 53(4):547-51. PubMed ID: 25510699
[TBL] [Abstract][Full Text] [Related]
40. Nomograms for predicting overall survival and cancer-specific survival of endometrioid ovarian carcinoma: A retrospective cohort study from the SEER database.
Wang D; Ran X; He Y; Zhu L; Deng Y
Int J Gynaecol Obstet; 2024 Apr; 165(1):194-202. PubMed ID: 38009672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
